{"nctId":"NCT00604214","briefTitle":"Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock","startDateStruct":{"date":"2008-03"},"conditions":["Sepsis"],"count":1696,"armGroups":[{"label":"Drotrecogin alfa (activated)","type":"EXPERIMENTAL","interventionNames":["Drug: Drotrecogin alfa (activated)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Drotrecogin alfa (activated)","otherNames":["LY203638","Xigris"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must be 18 years or older\n* Must have evidence of infection\n* Must have systemic inflammatory response syndrome (SIRS)\n* Must have vasopressor-dependent septic shock\n\nExclusion Criteria:\n\n* Have received vasopressor therapy (at any dose) for greater than 24 hours prior to the start of study drug\n* Have sepsis-induced organ dysfunction for greater than 36 hours prior to the start of the study drug infusion\n* Have single organ dysfunction and recent surgery (within 30 days of study entry)\n* Have had surgery performed within the 12-hour period immediately preceding the study drug infusion, or are postoperative with evidence of active bleeding, or have planned or anticipated surgery during the infusion period\n* Are not expected to survive 28 days given their preexisting uncorrectable medical condition","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"28-Day All-Cause Mortality","description":"Expressed as percentage of participants who died from any cause at Day 28 endpoint.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.4","spread":null},{"groupId":"OG001","value":"24.2","spread":null}]}]}]},{"type":"SECONDARY","title":"28-Day All-Cause Mortality in Participants With Severe Protein C Deficiency","description":"Expressed as percentage of participants who died from any cause at Day 28 endpoint. Participants with severe protein C deficiency are those who had a protein C level ≤ half the lower limit of normal (LLN) (≤40%).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.7","spread":null},{"groupId":"OG001","value":"30.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Cardiovascular Sequential Organ Failure Assessment (SOFA) Score Day 1 Through Day 28","description":"Scores range from 0 (normal) to 4 (organ failure) with an increasing score indicating increasing cardiovascular dysfunction. A non-surviving participant receives a score of 4 (worst score) for the day of death and every day thereafter.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.92","spread":"1.31"},{"groupId":"OG001","value":"1.84","spread":"1.31"}]}]}]},{"type":"SECONDARY","title":"Average Respiratory Sequential Organ Failure Assessment (SOFA) Score Day 1 Through Day 28","description":"Scores range from 0 (normal) to 4 (organ failure) with an increasing score indicating increasing respiratory dysfunction. A non-surviving participant receives a score of 4 (worst score) for the day of death and every day thereafter.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.31","spread":"1.05"},{"groupId":"OG001","value":"2.29","spread":"1.05"}]}]}]},{"type":"SECONDARY","title":"Average Renal Sequential Organ Failure Assessment (SOFA) Score Day 1 Through Day 28","description":"Scores range from 0 (normal) to 4 (organ failure) with an increasing score indicating increasing renal dysfunction. A non-surviving participant receives a score of 4 (worst score) for the day of death and every day thereafter.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.38","spread":"1.42"},{"groupId":"OG001","value":"1.28","spread":"1.40"}]}]}]},{"type":"SECONDARY","title":"90-Day Mortality","description":"Expressed as percentage of participants who died from any cause at Day 90 endpoint.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.1","spread":null},{"groupId":"OG001","value":"32.7","spread":null}]}]}]},{"type":"SECONDARY","title":"180-Day Mortality","description":"Expressed as percentage of participants who died from any cause at Day 180 endpoint.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.6","spread":null},{"groupId":"OG001","value":"35.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Survival Time","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"EuroQoL Questionnaire-5 Dimensions (EQ-5D) Visual Analog Scale (VAS) Scores at Baseline, Days 28, 90 and 180","description":"EQ-5D VAS assesses caregiver's impression of participant's overall health state. Scores range from 0 (worst health state) to 100 (best health state), with higher scores indicating a better health state.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.21","spread":"26.99"},{"groupId":"OG001","value":"54.37","spread":"27.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.78","spread":"23.46"},{"groupId":"OG001","value":"55.24","spread":"22.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.41","spread":"21.00"},{"groupId":"OG001","value":"65.18","spread":"20.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.94","spread":"20.19"},{"groupId":"OG001","value":"69.08","spread":"20.50"}]}]}]},{"type":"SECONDARY","title":"EuroQoL Questionnaire-5 Dimensions (EQ-5D) Total Scores at Baseline, Days 28, 90 and 180","description":"The EQ-5D is used to assess participant's overall health. Consists of 5 items: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each item has 3 severity levels (no, some, severe problems). Calculated from EQ-5D, total scores (United States \\[US\\] Index Score) range from 0 (worst quality of life) to 1.00 (best quality of life).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","spread":"0.35"},{"groupId":"OG001","value":"0.60","spread":"0.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.51","spread":"0.33"},{"groupId":"OG001","value":"0.53","spread":"0.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.71","spread":"0.27"},{"groupId":"OG001","value":"0.71","spread":"0.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.77","spread":"0.23"},{"groupId":"OG001","value":"0.76","spread":"0.25"}]}]}]},{"type":"SECONDARY","title":"Quality of Life Short Form-12 (SF-12) Scores at Baseline, Days 28, 90 and 180","description":"SF-12 was used as an instrument to measure participants' physical wellbeing (physical component) and mental wellbeing (mental component). Scores for each component range from 0-100, with 0= lowest wellbeing, and 100=highest wellbeing.","paramType":"MEDIAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.14","spread":"12.04"},{"groupId":"OG001","value":"39.22","spread":"12.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.14","spread":"10.29"},{"groupId":"OG001","value":"31.13","spread":"9.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.09","spread":"11.17"},{"groupId":"OG001","value":"40.03","spread":"11.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.26","spread":"10.80"},{"groupId":"OG001","value":"41.59","spread":"11.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.44","spread":"13.07"},{"groupId":"OG001","value":"46.03","spread":"12.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.57","spread":"13.12"},{"groupId":"OG001","value":"41.45","spread":"12.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.53","spread":"12.08"},{"groupId":"OG001","value":"48.52","spread":"12.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.42","spread":"11.50"},{"groupId":"OG001","value":"50.55","spread":"11.70"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Serious Bleeding Events Within System Organ Class Any Time From Baseline Through Day 28","description":"Percentage of participants who experienced serious bleeding events are reported by System Organ Class (SOC) term based on MedDRA 14.0. For a bleeding to qualify as a serious event, it would have to meet the standard definition of a serious adverse event or be a central nervous system bleeding or a bleeding event that lead to administration of ≥3 units packed red blood cells/day for 2 consecutive days.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null},{"groupId":"OG001","value":"2.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Discontinued Due to Adverse Events Any Time From Baseline Through Day 28 Endpoint","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":null},{"groupId":"OG001","value":"3.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":119,"n":833},"commonTop":["Thrombocytopenia","Haematuria","Deep vein thrombosis","Atrial fibrillation","Catheter site haemorrhage"]}}}